Please login to the form below

Not currently logged in
Email:
Password:

Vosevi

This page shows the latest Vosevi news and features for those working in and with pharma, biotech and healthcare.

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi

The results show that 97% of patients on Vosevi achieved the primary efficacy endpoint of a sustained viral response (SVR) for 12 or more weeks post-treatment. ... John Milligan, president and chief executive officer, Gilead, said: “The authorisation

Latest news

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The US FDA has approved Gilead Sciences' triple drug therapy Vosevi to treat hepatitis C Virus (HCV) as a back-up therapy for patients who can't eliminate the virus with ... The FDA has cleared the new product for all the most common HCV genotypes (1-6)

  • Samsung Bioepis wins CHMP nod for second Humira biosimilar Samsung Bioepis wins CHMP nod for second Humira biosimilar

    virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir). ... The CHMP notes that "both Maviret and Vosevi are active against all genotypes of the virus and with some differences between

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics